cytarabine has been researched along with navitoclax in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akao, Y; Horiike, S; Kobayashi, S; Kobayashi, T; Kuroda, J; Matsumoto, Y; Nagoshi, H; Nishida, K; Sasaki, N; Shimura, Y; Taki, T; Taniwaki, M; Tsutsumi, Y; Yamamoto, M | 1 |
1 other study(ies) available for cytarabine and navitoclax
| Article | Year |
|---|---|
Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Topics: Aniline Compounds; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Survival; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; Spectral Karyotyping; Sulfonamides; Thiazoles; Translocation, Genetic | 2011 |